Building

Pheon Therapeutics launched with $63 million in Series A financing and a vision of ushering in the next generation of antibody-drug conjugates.

Microscope, lab

TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.

Eli Lilly

Today’s promising results from Eisai and Biogen’s Alzheimer’s drug trial have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.

Biogen

An experimental Alzheimer’s drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.

Klick IDX, Leerom Segal, Barack Obama

With a range of heavy-hitting speakers, including former President Barack Obama, attendees gathered at the Brooklyn Navy Yard to learn more about the possibilities of the future of healthcare and biomedicine, and reflect on lessons learned from the past.

Sanofi

Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.

Tokyo, Japan, Shibuya, masks

Japan’s population level immunity to COVID-19 has reached about 90% in major population areas after a recent Omicron wave, though that level of protection is likely to diminish in a matter of months, according to a study published on Tuesday.

The agency put the partial hold after a serious adverse event was seen in a patient during the study.

FDA, stop sign

In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra (duvelisib).

Modifi Bio

September is Childhood Cancer Awareness Month, which sheds light on the need for new developments in pediatric oncology. For American children, the number one cause of death by disease is cancer. Pediatric gliomas, the most common type of brain tumor in children, are a critical area of focus for oncology research.